blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3436459

EP3436459 - FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.07.2022
Database last updated on 28.05.2024
FormerThe patent has been granted
Status updated on  23.07.2021
FormerGrant of patent is intended
Status updated on  06.04.2021
FormerExamination is in progress
Status updated on  06.07.2020
FormerRequest for examination was made
Status updated on  04.01.2019
FormerThe international publication has been made
Status updated on  07.10.2017
Formerunknown
Status updated on  11.04.2017
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024 [2024/22]
Applicant(s)For all designated states
UCB Biopharma SRL
Allée de la Recherche 60
1070 Brussels / BE
For all designated states
Sanofi
54 Rue de la Boetie
75008 Paris / FR
[2021/34]
Former [2020/02]For all designated states
UCB Biopharma SRL
Allé de la Recherche 60
1070 Brussels / BE
For all designated states
Sanofi
54 Rue de la Boetie
75008 Paris / FR
Former [2019/06]For all designated states
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels / BE
For all designated states
Sanofi
54 Rue de la Boetie
75008 Paris / FR
Inventor(s)01 / DELIGNY, Michaël Louis Robert
c/o IPD
UCB Biopharma SPRL
Allée de la Recherche 60
B-1070 Brussels / BE
02 / HEER, Jag Paul
c/o IPD
UCB Celltech
208 Bath Road
Slough Berkshire SL1 3WE / GB
 [2019/06]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2021/34]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2019/06]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date17714783.231.03.2017
[2019/06]
WO2017EP57765
Priority number, dateEP2016016357101.04.2016         Original published format: EP 16163571
[2019/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017167993
Date:05.10.2017
Language:EN
[2017/40]
Type: A1 Application with search report 
No.:EP3436459
Date:06.02.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 05.10.2017 takes the place of the publication of the European patent application.
[2019/06]
Type: B1 Patent specification 
No.:EP3436459
Date:25.08.2021
Language:EN
[2021/34]
Search report(s)International search report - published on:EP05.10.2017
ClassificationIPC:C07D487/04, C07D487/18, A61P3/00, A61P9/00, A61P25/00, A61P25/04, A61P25/28, A61P27/00, A61P35/00, C07D519/00, A61P29/00, A61P37/02, C07D487/22, A61P43/00, A61K31/4188
[2021/15]
CPC:
C07D519/00 (EP,US); C07D487/04 (EP,EA,US); A61P25/00 (EP);
A61P25/04 (EP); A61P25/28 (EP,US); A61P27/00 (EP);
A61P29/00 (EP); A61P3/00 (EP); A61P35/00 (EP,US);
A61P37/02 (EP); A61P43/00 (EP); A61P9/00 (EP,US);
C07D487/18 (EP,EA,US); C07D487/22 (EP,US); A61P3/10 (EP,US);
A61P37/04 (EP,US) (-)
Former IPC [2021/14]A61P3/00, A61P9/00, A61P25/00, A61P25/04, A61P25/28, A61P27/00, A61P29/00, A61P35/00, A61P43/00, C07D487/22, C07D519/00, C07D487/04, C07D487/18, A61P37/02
Former IPC [2019/06]C07D487/04, C07D487/18, A61K31/428, A61K31/4188
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/06]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:KONDENSIERTE PENTACYCLISCHE IMIDAZOL-DERIVATE ALS MODULATOREN DER TNF-AKTIVITÄT[2021/14]
English:FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY[2019/06]
French:DÉRIVÉS D'IMIDAZOLE PENTACYCLIQUE FUSIONNÉS COMME MODULATEURS DE L'ACTIVITÉ DE LA TNF[2021/14]
Former [2019/06]KONDENSIERTE PENTACYCLISCHE DERIVATE ALS MODULATOREN DER TNF-AKTIVITÄT
Former [2019/06]DÉRIVÉS D'IMIDAZOLE PENTACYCLIQUES CONDENSÉS UTILISÉS EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU TNF
Entry into regional phase29.10.2018National basic fee paid 
29.10.2018Designation fee(s) paid 
29.10.2018Examination fee paid 
Examination procedure29.10.2018Examination requested  [2019/06]
29.10.2018Date on which the examining division has become responsible
17.05.2019Amendment by applicant (claims and/or description)
09.07.2020Despatch of a communication from the examining division (Time limit: M04)
04.11.2020Reply to a communication from the examining division
07.04.2021Communication of intention to grant the patent
20.07.2021Fee for grant paid
20.07.2021Fee for publishing/printing paid
20.07.2021Receipt of the translation of the claim(s)
Opposition(s)27.05.2022No opposition filed within time limit [2022/31]
Fees paidRenewal fee
13.03.2019Renewal fee patent year 03
12.03.2020Renewal fee patent year 04
12.03.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU31.03.2017
AL25.08.2021
AT25.08.2021
CY25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
IT25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
MK25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
BE31.03.2022
CH31.03.2022
IE31.03.2022
LI31.03.2022
LU31.03.2022
[2024/22]
Former [2024/20]HU31.03.2017
AL25.08.2021
AT25.08.2021
CY25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
IT25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
BE31.03.2022
CH31.03.2022
IE31.03.2022
LI31.03.2022
LU31.03.2022
Former [2024/18]HU31.03.2017
AL25.08.2021
AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
IT25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
BE31.03.2022
CH31.03.2022
IE31.03.2022
LI31.03.2022
LU31.03.2022
Former [2023/10]AL25.08.2021
AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
IT25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
BE31.03.2022
CH31.03.2022
IE31.03.2022
LI31.03.2022
LU31.03.2022
Former [2023/09]AL25.08.2021
AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
IT25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
CH31.03.2022
IE31.03.2022
LI31.03.2022
LU31.03.2022
Former [2023/08]AL25.08.2021
AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
IT25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
IE31.03.2022
LU31.03.2022
Former [2022/47]AL25.08.2021
AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
IT25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/36]AL25.08.2021
AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
IT25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/29]AL25.08.2021
AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/25]AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SK25.08.2021
SM25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/24]AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
RS25.08.2021
SE25.08.2021
SK25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/21]AT25.08.2021
DK25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
RS25.08.2021
SE25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/16]AT25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
RS25.08.2021
SE25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/10]AT25.08.2021
ES25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
PL25.08.2021
RS25.08.2021
SE25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
PT27.12.2021
Former [2022/09]AT25.08.2021
ES25.08.2021
FI25.08.2021
LT25.08.2021
RS25.08.2021
SE25.08.2021
BG25.11.2021
NO25.11.2021
PT27.12.2021
Former [2022/08]AT25.08.2021
ES25.08.2021
FI25.08.2021
LT25.08.2021
SE25.08.2021
BG25.11.2021
NO25.11.2021
Former [2022/07]AT25.08.2021
LT25.08.2021
NO25.11.2021
Cited inInternational search[Y]WO2014009295  (UCB PHARMA SA [BE]) [Y] 1-14 * page 2, lines 14-23, "The compounds potently neutralise the activity on TNF alpha....When tested in the HEK-293 bioassay...of 20 nM or less.."; page 103, line 17 - page 104, line 2; examples; claims, e.g. Claims 5, 6, 7, 14-19 *;
 [Y]US2015152065  (BROOKINGS DANIEL CHRISTOPHER [GB], et al) [Y] 1-14 * [0007], "When tested in the HEK-293 bioassay.....of 20 nM or less"; [0455]-[0456]; page 45, Intermediate 65; page 46, Intermediate 72; page 83, Example 447; page 85, Example 475; page 91, Example 535; page 107, Example 827; page 122, Example 1060; page 123, Example 1069; claims *;
 [Y]WO2015086525  (UCB BIOPHARMA SPRL [BE]) [Y] 1-14* page 64, line 9 - page 65, line 11; page 100, line 5 - page 102, line 6; examples, e.g. Examples 84, 169, 181, 205; claims, e.g. Claims 11, 22-25 *
by applicantWO2004087720
 WO2009156091
 WO2012135082
 WO2012177707
 WO2013186229
 WO2014009295
 WO2014009296
 WO2015086525
 WO2015086526
 WO2016050975
    - M.G. TANSEY; D.E. SZYMKOWSKI, DRUG DISCOVERY TODAY, (2009), vol. 14, pages 1082 - 1088
    - F.S. CARNEIRO ET AL., J. SEXUAL MEDICINE, (2010), vol. 7, pages 3823 - 3834
    - J.J. WU ET AL., JAMA, (2013), vol. 309, pages 2043 - 2044
    - F.V. HAUWERMEIREN ET AL., J. CLIN. INVEST., (2013), vol. 123, pages 2590 - 2603
    - STAMBULI J. ET AL., J. ORG. CHEM., (2009), vol. 74, pages 4005 - 4008
    - K. BAHRAMI; M.M. KHODAEI; M. SOHEILIZAD, J. ORG. CHEM., (2009), vol. 74, pages 9287 - 9291
    - H. HILPERT ET AL., JOURNAL OF MEDICINAL CHEMISTRY, (2013), vol. 56, no. 10, pages 3980 - 3995
    - M. KERR ET AL., J. ORG. CHEM., (2013), vol. 78, page 10534
    - SAKAI ET AL., J. ORG. CHEM., (2007), vol. 72, pages 5920 - 5922
    - OKAMURA, H. ET AL., ORGANIC LETTERS, (2004), vol. 6, no. 8, pages 1305 - 1307
    - MCMILLAN ET AL., NATURE, (2011), vol. 480, page 224
    - S. P. GREEN ET AL., ORGANIC PROCESS RESEARCH & DEVELOPMENT, (2002), vol. 6, pages 109 - 112
    - NAM, N-H. ET AL., BIO-ORG. MED. CHEM., (2004), vol. 12, page 6255
    - E. LACKO ET AL., CURRENT MEDICINAL CHEMISTRY, (2012), vol. 19, page 4699
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.